Mesenchymal Stem Cell Therapy for COVID-19: Present or Future

Area of Science:

• Biomedical research
• Immunology
• Regenerative medicine

Background:

• The COVID-19 pandemic has spurred research into novel treatments due to the lack of a standard cure.
• Severe acute respiratory illness is the most dangerous phase of COVID-19, necessitating preventative and therapeutic strategies.
• Mesenchymal stem cells (MSCs) possess immunomodulatory and regenerative properties, making them a potential therapeutic agent.

Purpose of the Study:

• To review current clinical trials and hypotheses regarding MSC-based immunomodulation for COVID-19.
• To provide information for researchers and clinicians interested in stem cell therapy for COVID-19.
• To discuss the potential of MSCs in improving immunological responses and treating lung dysfunction in COVID-19 patients.

Main Methods:

• Review of reported clinical trials involving MSCs for COVID-19.
• Analysis of the proposed mechanisms of MSC action in the context of COVID-19.
• Discussion of the potential benefits and current limitations of MSC-based therapy.

Main Results:

• MSCs accumulate in the lungs after intravenous transplantation, exerting immunomodulatory effects.
• Potential benefits include protection of alveolar epithelial cells, restoration of the pulmonary environment, prevention of fibrosis, and cure of lung dysfunction.
• Several clinical trials have been initiated to evaluate MSC therapy for COVID-19.

Conclusions:

• MSC-based immunomodulation is a promising therapeutic approach for managing severe COVID-19.
• While not yet approved, ongoing clinical trials are investigating the efficacy and safety of MSCs.
• Further research is needed to establish approved MSC-based treatments for COVID-19 prevention and/or management.